Pfizer, Medicus ink licensing deal worth up to $1B for antibody drug conjugate

Summary

Pfizer and Medicus announced a licensing agreement for an antibody drug conjugate with potential deal value up to $1 billion. The partnership demonstrates Pfizer's strategy to monetize its antibody drug conjugate portfolio through licensing arrangements.